DuoCagriSema
Two mechanisms. One protocol.
About
What it is
CagriSema combines cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) into a single injection. Two distinct satiety pathways working together — clinical trials show results exceeding either component alone.
How it works
CagriSema combines two mechanisms: cagrilintide activates amylin receptors for satiety, while semaglutide activates GLP-1 receptors for appetite suppression and metabolic improvement. The dual pathway produces additive effects.
Benefits
Who it's for
What to expect
Week 1–2
Dual appetite suppression begins. Adjustment period.
Week 4–6
Strong appetite control from both pathways.
Week 8–12
Significant weight loss exceeding single-agent approaches.
Week 24+
Maximum efficacy. Clinical data shows superior results vs. either component alone.
Safety & tolerability
Both components have individual safety profiles from clinical trials. The combination has been studied in Phase 3 trials. Side effects are consistent with each component. Our care team manages titration carefully.
How we compound
Single-source API
Every peptide is sourced from one vetted pharmaceutical-grade supplier — no blending from multiple sources.
Third-party tested
Independent labs verify purity, potency, sterility, and endotoxin levels before any batch is released.
Care team reviewed
A real person reviews your profile, your protocol, and your progress. Not an algorithm.
Weight Loss
DuoCagriSema
Every protocol is reviewed by our care team before it ships. Questions? Learn more
$279/mo
You might also consider
ContourSemaglutide
The GLP-1 that changed weight management forever.
EvolveTirzepatide
Dual-action GLP-1/GIP. The next generation of weight management.
Apex-3Retatrutide
Triple agonist. Three pathways. One injection.